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Obesity has emerged as one of the major global epidemics of the 21st century and 
is now reaching alarming proportions. Obese subjects have an increased morbidity 
and mortality, decreased quality of life, and a major risk of developing co-morbidities 
such as diabetes and insulin resistance. Obesity is a complex disease characterised 
by an increase in body fat mass resulting from an imbalance between energy intake 
and expenditure. Proteomics may be useful in unravelling the pathogenesis of obesity, 
since a combination of genetic predisposition and environmental factors account for its 
development.
Adipose tissue plays a major role in obesity, not only for its capacity to store and 
metabolise lipids, but also for its ability to act as an endocrine organ. Adipose tissue is 
a complex organ and contains several cell types, namely the adipocytes, and stromal 
fraction (macrophages, endothelial cells, vascular cells). We are currently investigating 
the alterations in the adipocyte and stromal fraction proteome of visceral adipose tissue. 
Tissue samples were obtained from obese subjects (body mass index, BMI >40 kg/
m2) undergoing bariatric surgery with different degrees of glucose tolerance (diabetic, 
glucose intolerant and normal) and lean subjects (BMI 20-25 kg/m2). Protein extracts 
were analysed by DIGE, and proteins identified by MS/MS. Candidate proteins in 
the adipocyte fraction overexpressed in obesity include carboxylesterase, GRP78, 
transketolase, catalase; and hsp60, UQCRC1 and perilipin were down-regulated.
Target identification of the potential anti-obesity agent sodium tungstate has also been 
investigated using 2D and DIGE. Oral administration of tungstate reduced body weight 
gain and adiposity, and improved dyslipemia and insulin resistance in cafeteria diet-
induced rats. Tungstate is currently undergoing phase II clinical trials. In white adipose 
tissue we found that tungstate treatment reversed the expression changes of 70% of the 
proteins modified in obesity and was able to modulate cellular structure, metabolism, 
redox, and signalling processes. In brown adipose tissue, tungstate modulates redox 
processes and increases energy dissipation through uncoupling and up-regulation of 
PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α).
The work presented here was mainly done at the Laboratory of Diabetes and Obesity, IDIBAPS, Hospital 
Clínic de Barcelona, Catalonia, Spain.
